Disc Medicine, Inc. (IRON) Stock Analysis

Q: What is the IRON stock price target?

Take-profit $87.95 (+31.6% upside). Prior stop was $63.03.

Q: What are the risks of investing in IRON?

Concentration risk — Pipeline: bitopertin; Quality below floor (1.2 < 4.0); Value-trap signals (3/5): Margin compression (op margin -5.9%), High leverage (D/E 4.5), Material insider selling (43 sells, 0.44% of cap); Quality below floor (1.2 < 4.0); Value-trap signals (3/5): Margin compression (op margin -5.9%), High leverage (D/E 4.5), Material insider selling (43 sells, 0.44% of cap).

Q: Is IRON overvalued or undervalued?

Disc Medicine, Inc. trades at a P/E of N/A (forward -8.9). TrendMatrix value score: 9.0/10. Overall verdict: Sell.

Q: What do analysts say about IRON?

19 analysts cover IRON with a consensus score of 4.3/5. Average price target: $101.

SellVALUE-TRAP 3/5Moderate ConfidenceUpdated 1 days ago (May 19, 2026, 8:01 AM ET)

Healthcare · Biotechnology

Disc Medicine is a clinical-stage biopharmaceutical company developing treatments for hematologic diseases via heme biosynthesis modulation and iron homeostasis, with lead asset bitopertin for erythropoietic porphyrias in Phase 3 APOLLO trial following a February 2026 FDA... Read more

$66.91+31.6% A.UpsideScore 4.8/10#117 of 157 Biotechnology

QualityF-score2 / 9FCF yield-4.75%

Stop $63.03Target $87.95(analyst − 13%)A.R:R 3.3:1

Analyst target$101.09+51.1%11 analysts

$87.95our TP

$66.91price

$101.09mean

$128

Sell if holding. Engine safety override at $66.91: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 3.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.8/10, moderate confidence.

Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.70, earnings proximity 79d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and news legal. Suitability: aggressive.

Recent Developments — Disc Medicine, Inc.

Latest news

Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $80 — benzinga May 14, 2026 positive
'Makary's Time Atop FDA Over, Diamantas Named Acting Commissioner' - Politico — benzinga May 12, 2026 neutral
'Trump Approves Plan To Fire FDA Commissioner Marty Makary, Sources Say' - CBS — benzinga May 11, 2026 negative
Watching Sarepta Therapeutics, Disc Medicine; Shares See Volume To The Upside After WSJ Reports "Trump Planning to Fire — benzinga May 8, 2026 positive
Disc Medicine Q1 EPS $(1.65) Beats $(1.73) Estimate — benzinga May 5, 2026 positive

Generated 2026-05-20T20:21:21Z.

Thesis

Rewards

Recent Analyst detected in news

Risks

Concentration risk — Pipeline: bitopertin

Quality below floor (1.2 < 4.0)

Value-trap signals (3/5): Margin compression (op margin -5.9%), High leverage (D/E 4.5), Material insider selling (43 sells, 0.44% of cap)

Key Metrics

P/E (TTM)—

P/E (Fwd)-8.9

Mkt Cap$2.6B

EV/EBITDA-7.0

Profit Mgn0.0%

ROE-35.8%

Rev Growth—

Beta2.14

DividendNone

Rating analysts19

Quality Signals

Piotroski F2/9

Options Flow

P/C0.01bullish

IV60%elevated

Max Pain$110+64.4% vs spot

Concentration Risks(10-K Item 1A)

HIGHpipelinebitopertin
10-K Item 1: 'Bitopertin is the lead product candidate in our heme biosynthesis modulation portfolio...the FDA accepted our NDA for review in November 2025 and in February 2026 issued a complete response letter'

Material Events(8-K, last 90d)

2026-02-27Item 2.05MEDIUM
Board approved restructuring plan on February 26, 2026 reducing workforce ~20%, primarily commercial functions, following FDA complete response letter for bitopertin NDA. Expected aggregate charges ~$2.0M (primarily severance) to be recorded primarily in Q1 2026.
SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers·1 ceiling hit

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value9.015%1.35

Quality1.215%0.18

Growth5.015%0.75

Momentum2.910%0.29

Sentiment7.710%0.77

Insider Activity3.810%0.38

Peer Rank4.110%0.41

Technical Setup5.65%0.28

Risk Profile3.55%0.18

Catalyst4.15%0.20

Overall (Σ contributions)4.79

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe

0.0

Roa

0.0

Gross Margin

0.0

Operating Margin

0.0

Net Margin

0.0

Fcf Quality

0.0

Piotroski F

2.2

Moat

3.2

Current Ratio

5.0

Cash-burning (FCF negative)No competitive moatWeak Piotroski F-Score: 2/9Quality concerns

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd

0.0

Obv

1.0

Ma Position

4.2

Rsi

4.5

Volume

4.9

Volume distribution (falling OBV)Below 200-MA but MA still rising (+2.6%/30d) — pullback in uptrend, not confirmed weakness

GatesMomentum 2.9<4.5NEWS LEGALA.R:R 3.3 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS BOOST ANALYST 0.70EARNINGS PROXIMITY 79d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive

RSI

48 · Neutral

↓ 20D MA↑ 50D MA↓ 200D MADEATH CROSSSupport $64.98Resistance $72.81

Price Targets

$63

$88

A.Upside+31.4%

A.R:R3.3:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Quality below floor (1.2 < 4.0)

! Value-trap signals (3/5): Margin compression (op margin -5.9%), High leverage (D/E 4.5), Material insider selling (43 sells, 0.44% of cap)

! Momentum score 2.9/10 — below 4.5 minimum

Earnings

2/4 beats

Next Earnings2026-08-06 (79d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is IRON stock a buy right now?

Sell if holding. Engine safety override at $66.91: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 3.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $63.03. Score 4.8/10, moderate confidence.

What is the IRON stock price target?

Take-profit target: $87.95 (+31.6% upside). Prior stop was $63.03. Stop-loss: $63.03.

What are the risks of investing in IRON?

Concentration risk — Pipeline: bitopertin; Quality below floor (1.2 < 4.0); Value-trap signals (3/5): Margin compression (op margin -5.9%), High leverage (D/E 4.5), Material insider selling (43 sells, 0.44% of cap).

Is IRON overvalued or undervalued?

Disc Medicine, Inc. trades at a P/E of N/A (forward -8.9). TrendMatrix value score: 9.0/10. Verdict: Sell.

What do analysts say about IRON?

19 analysts cover IRON with a consensus score of 4.3/5. Average price target: $101.

What does Disc Medicine, Inc. do?Disc Medicine is a clinical-stage biopharmaceutical company developing treatments for hematologic diseases via heme...